Answers are grounded in this paper and cite their sources.
OBJECTIVE: To discuss the value of intratympanic dexamethasone (IT-DEX) perfusion for sudden sensorineural hearing loss (SSNHL), clinically and in an animal model. STUDY DESIGN: Retrospective case review of 10 patients with SSNHL treated with IT-DEX. The findings are correlated with this institution's previous findings from a study of IT-DEX in guinea pigs. SETTING: Ambulatory tertiary otologic referral center. PATIENTS: Sequential patients with SSNHL who chose IT-DEX treatment. INTERVENTIONS: Dexamethasone 0.5 mg was injected transtympanically and bathed the round window for 20 minutes. Animal study: 79 ears were randomized into five groups: control, IT-DEX versus intravenous (IV)-DEX, IT-DEX with histamine, IT-DEX with hyaluronic acid, and IT-DEX with dimethylsulfoxide. MAIN OUTCOME MEASURES: Clinical study: postprocedure audiometry. Animal study: perilymph steroid concentration. RESULTS: IT-DEX results in significant hearing improvement and in significantly higher perilymph concentration of steroid than IV-DEX. CONCLUSIONS: IT-DEX is an appropriate treatment option for the treatment of SSNHL. Further study of dosages and frequency of administration is warranted.
No takes yet. Share an insight, caveat, or question.
Sujana S. Chandrasekhar (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: